Trial Profile

Open-Label Phase 1 Study of PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PD-L1-t-haNK (Primary)
Indications Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors ImmunityBio; NantKwest

Most Recent Events

19 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 31 Oct 2024.
05 Feb 2024 Planned End Date changed from 18 Dec 2023 to 30 Dec 2024.
05 Feb 2024 Planned primary completion date changed from 18 Sep 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com